Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 146

1.

SIE, SIES, GITMO evidence-based guidelines on novel agents (thalidomide, bortezomib, and lenalidomide) in the treatment of multiple myeloma.

Barosi G, Merlini G, Billio A, Boccadoro M, Corradini P, Marchetti M, Massaia M, Tosi P, Palumbo A, Cavo M, Tura S.

Ann Hematol. 2012 Jun;91(6):875-88. doi: 10.1007/s00277-012-1445-y. Epub 2012 Apr 4. Review.

PMID:
22476884
2.

Treatment of multiple myeloma: 2009 update.

[No authors listed]

Prescrire Int. 2009 Dec;18(104):263-6.

PMID:
20025098
3.

Shifts in the therapeutic paradigm for patients newly diagnosed with multiple myeloma: maintenance therapy and overall survival.

Palumbo A, Attal M, Roussel M.

Clin Cancer Res. 2011 Mar 15;17(6):1253-63. doi: 10.1158/1078-0432.CCR-10-1925. Review.

4.

Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance in untreated multiple myeloma patients.

Palumbo A, Gay F, Falco P, Crippa C, Montefusco V, Patriarca F, Rossini F, Caltagirone S, Benevolo G, Pescosta N, Guglielmelli T, Bringhen S, Offidani M, Giuliani N, Petrucci MT, Musto P, Liberati AM, Rossi G, Corradini P, Boccadoro M.

J Clin Oncol. 2010 Feb 10;28(5):800-7. doi: 10.1200/JCO.2009.22.7561. Epub 2010 Jan 4. Erratum in: J Clin Oncol. 2010 May 1;28(13):2314.

PMID:
20048187
5.

Advances in therapy of multiple myeloma.

Bladé J, Rosiñol L.

Curr Opin Oncol. 2008 Nov;20(6):697-704. doi: 10.1097/CCO.0b013e3283136984. Review.

PMID:
18841053
6.

Treatment of multiple myeloma in the targeted therapy era.

Saad AA, Sharma M, Higa GM.

Ann Pharmacother. 2009 Feb;43(2):329-38. doi: 10.1345/aph.1L428. Epub 2009 Feb 3. Review.

PMID:
19193585
7.

Sequential bortezomib, dexamethasone, and thalidomide maintenance therapy after single autologous peripheral stem cell transplantation in patients with multiple myeloma.

Sahebi F, Frankel PH, Farol L, Krishnan AY, Cai JL, Somlo G, Thomas SH, Reburiano E, Popplewell LL, Parker PM, Spielberger RT, Kogut NM, Karanes C, Htut M, Ruel C, Duarte L, Murata-Collins JL, Forman SJ.

Biol Blood Marrow Transplant. 2012 Mar;18(3):486-92. doi: 10.1016/j.bbmt.2011.12.580. Epub 2011 Dec 22.

8.

Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial.

Palumbo A, Bringhen S, Rossi D, Cavalli M, Larocca A, Ria R, Offidani M, Patriarca F, Nozzoli C, Guglielmelli T, Benevolo G, Callea V, Baldini L, Morabito F, Grasso M, Leonardi G, Rizzo M, Falcone AP, Gottardi D, Montefusco V, Musto P, Petrucci MT, Ciccone G, Boccadoro M.

J Clin Oncol. 2010 Dec 1;28(34):5101-9. doi: 10.1200/JCO.2010.29.8216. Epub 2010 Oct 12.

PMID:
20940200
9.

Integrating novel therapies in the transplant paradigm.

Harousseau JL.

Cancer J. 2009 Nov-Dec;15(6):479-84. doi: 10.1097/PPO.0b013e3181c51ca3. Review.

PMID:
20010167
10.

Pegylated liposomal doxorubicin in combination with dexamethasone and bortezomib (VMD) or lenalidomide (RMD) in multiple myeloma pretreated patients.

Buda G, Orciuolo E, Galimberti S, Pelosini M, Petrini M.

Ann Hematol. 2011 Sep;90(9):1115-6. doi: 10.1007/s00277-010-1136-5. Epub 2010 Dec 22. No abstract available. Erratum in: Ann Hematol. 2011 Jul;90(7):863.

PMID:
21181162
11.

Novel agents for relapsed and/or refractory multiple myeloma.

Thomas SK, Richards TA, Weber DM.

Cancer J. 2009 Nov-Dec;15(6):485-93. doi: 10.1097/PPO.0b013e3181c51cba. Review.

PMID:
20010168
12.

Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy.

Sonneveld P, Hajek R, Nagler A, Spencer A, Bladé J, Robak T, Zhuang SH, Harousseau JL, Orlowski RZ; DOXIL-MMY-3001 Study Investigators.

Cancer. 2008 Apr 1;112(7):1529-37. doi: 10.1002/cncr.23326.

13.

Treatment options for relapsed and refractory multiple myeloma.

Lonial S, Mitsiades CS, Richardson PG.

Clin Cancer Res. 2011 Mar 15;17(6):1264-77. doi: 10.1158/1078-0432.CCR-10-1805. Review.

14.

Treatment of newly diagnosed myeloma.

Palumbo A, Rajkumar SV.

Leukemia. 2009 Mar;23(3):449-56. doi: 10.1038/leu.2008.325. Epub 2008 Nov 13. Review.

15.

Bortezomib, thalidomide, and dexamethasone as induction therapy for patients with symptomatic multiple myeloma: a retrospective study.

Kaufman JL, Nooka A, Vrana M, Gleason C, Heffner LT, Lonial S.

Cancer. 2010 Jul 1;116(13):3143-51. doi: 10.1002/cncr.25143.

16.

Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma.

Moreau P, Avet-Loiseau H, Facon T, Attal M, Tiab M, Hulin C, Doyen C, Garderet L, Randriamalala E, Araujo C, Lepeu G, Marit G, Caillot D, Escoffre M, Lioure B, Benboubker L, Pégourié B, Kolb B, Stoppa AM, Fuzibet JG, Decaux O, Dib M, Berthou C, Chaleteix C, Sebban C, Traullé C, Fontan J, Wetterwald M, Lenain P, Mathiot C, Harousseau JL.

Blood. 2011 Nov 24;118(22):5752-8; quiz 5982. doi: 10.1182/blood-2011-05-355081. Epub 2011 Aug 17.

17.

Bortezomib in the front-line treatment of multiple myeloma.

Richardson PG, Mitsiades C, Schlossman R, Ghobrial I, Hideshima T, Munshi N, Anderson KC.

Expert Rev Anticancer Ther. 2008 Jul;8(7):1053-72. doi: 10.1586/14737140.8.7.1053. Review.

PMID:
18588451
18.

Future drug developments in multiple myeloma: an overview of novel lenalidomide-based combination therapies.

Morgan G.

Blood Rev. 2010 Nov;24 Suppl 1:S27-32. doi: 10.1016/S0268-960X(10)70006-0.

PMID:
21126634
19.

The role of novel agents on the reversibility of renal impairment in newly diagnosed symptomatic patients with multiple myeloma.

Dimopoulos MA, Roussou M, Gkotzamanidou M, Nikitas N, Psimenou E, Mparmparoussi D, Matsouka C, Spyropoulou-Vlachou M, Terpos E, Kastritis E.

Leukemia. 2013 Feb;27(2):423-9. doi: 10.1038/leu.2012.182. Epub 2012 Jul 5.

PMID:
22763386
20.

"Short course" bortezomib plus melphalan and prednisone as induction prior to transplant or as frontline therapy for nontransplant candidates in patients with previously untreated multiple myeloma.

Gasparetto C, Gockerman JP, Diehl LF, de Castro CM, Moore JO, Long GD, Horwitz ME, Keogh G, Chute JP, Sullivan KM, Neuwirth R, Davis PH, Sutton LM, Anderson RD, Chao NJ, Rizzieri D.

Biol Blood Marrow Transplant. 2010 Jan;16(1):70-7. doi: 10.1016/j.bbmt.2009.08.017. Epub 2009 Sep 3.

Supplemental Content

Support Center